The cost of multiple sclerosis drugs in the US and the pharmaceutical industry

Daniel M. Hartung, Dennis Bourdette, Sharia M. Ahmed, Ruth Whitham

Research output: Contribution to journalArticle

115 Citations (Scopus)

Abstract

Objective: To examine the pricing trajectories in the United States of disease-modifying therapies (DMT) for multiple sclerosis (MS) over the last 20 years and assess the influences on rising prices. Methods: We estimated the trend in annual drug costs for 9 DMTs using published drug pricing data from 1993 to 2013. We compared changes in DMT costs to general and prescription drug inflation during the same period. We also compared the cost trajectories for first-generation MS DMTs interferon (IFN)-β-1b, IFN-β-1a IM, and glatiramer acetate with contemporaneously approved biologic tumor necrosis factor (TNF) inhibitors. Results: First-generation DMTs, originally costing $8,000 to $11,000, now cost about $60,000 per year. Costs for these agents have increased annually at rates 5 to 7 times higher than prescription drug inflation. Newer DMTs commonly entered the market with a cost 25%-60% higher than existing DMTs. Significant increases in the cost trajectory of the first-generation DMTs occurred following the Food and Drug Administration approvals of IFN-β-1a SC (2002) and natalizumab (reintroduced 2006) and remained high following introduction of fingolimod (2010). Similar changes did not occur with TNF inhibitor biologics during these time intervals. DMT costs in the United States currently are 2 to 3 times higher than in other comparable countries. Conclusions: MS DMT costs have accelerated at rates well beyond inflation and substantially above rates observed for drugs in a similar biologic class. There is an urgent need for clinicians, payers, and manufacturers in the United States to confront the soaring costs of DMTs.

Original languageEnglish (US)
Pages (from-to)2185-2192
Number of pages8
JournalNeurology
Volume84
Issue number21
DOIs
StatePublished - May 26 2015

Fingerprint

Drug Industry
Multiple Sclerosis
Costs and Cost Analysis
Pharmaceutical Preparations
Economic Inflation
Interferons
Prescription Drugs
Tumor Necrosis Factor-alpha
Drug Approval
Drug Costs
United States Food and Drug Administration
Therapeutics
Biological Products

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

The cost of multiple sclerosis drugs in the US and the pharmaceutical industry. / Hartung, Daniel M.; Bourdette, Dennis; Ahmed, Sharia M.; Whitham, Ruth.

In: Neurology, Vol. 84, No. 21, 26.05.2015, p. 2185-2192.

Research output: Contribution to journalArticle

Hartung, Daniel M. ; Bourdette, Dennis ; Ahmed, Sharia M. ; Whitham, Ruth. / The cost of multiple sclerosis drugs in the US and the pharmaceutical industry. In: Neurology. 2015 ; Vol. 84, No. 21. pp. 2185-2192.
@article{3b5adf4f753e49828d4ae8a9278e61d9,
title = "The cost of multiple sclerosis drugs in the US and the pharmaceutical industry",
abstract = "Objective: To examine the pricing trajectories in the United States of disease-modifying therapies (DMT) for multiple sclerosis (MS) over the last 20 years and assess the influences on rising prices. Methods: We estimated the trend in annual drug costs for 9 DMTs using published drug pricing data from 1993 to 2013. We compared changes in DMT costs to general and prescription drug inflation during the same period. We also compared the cost trajectories for first-generation MS DMTs interferon (IFN)-β-1b, IFN-β-1a IM, and glatiramer acetate with contemporaneously approved biologic tumor necrosis factor (TNF) inhibitors. Results: First-generation DMTs, originally costing $8,000 to $11,000, now cost about $60,000 per year. Costs for these agents have increased annually at rates 5 to 7 times higher than prescription drug inflation. Newer DMTs commonly entered the market with a cost 25{\%}-60{\%} higher than existing DMTs. Significant increases in the cost trajectory of the first-generation DMTs occurred following the Food and Drug Administration approvals of IFN-β-1a SC (2002) and natalizumab (reintroduced 2006) and remained high following introduction of fingolimod (2010). Similar changes did not occur with TNF inhibitor biologics during these time intervals. DMT costs in the United States currently are 2 to 3 times higher than in other comparable countries. Conclusions: MS DMT costs have accelerated at rates well beyond inflation and substantially above rates observed for drugs in a similar biologic class. There is an urgent need for clinicians, payers, and manufacturers in the United States to confront the soaring costs of DMTs.",
author = "Hartung, {Daniel M.} and Dennis Bourdette and Ahmed, {Sharia M.} and Ruth Whitham",
year = "2015",
month = "5",
day = "26",
doi = "10.1212/WNL.0000000000001608",
language = "English (US)",
volume = "84",
pages = "2185--2192",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "21",

}

TY - JOUR

T1 - The cost of multiple sclerosis drugs in the US and the pharmaceutical industry

AU - Hartung, Daniel M.

AU - Bourdette, Dennis

AU - Ahmed, Sharia M.

AU - Whitham, Ruth

PY - 2015/5/26

Y1 - 2015/5/26

N2 - Objective: To examine the pricing trajectories in the United States of disease-modifying therapies (DMT) for multiple sclerosis (MS) over the last 20 years and assess the influences on rising prices. Methods: We estimated the trend in annual drug costs for 9 DMTs using published drug pricing data from 1993 to 2013. We compared changes in DMT costs to general and prescription drug inflation during the same period. We also compared the cost trajectories for first-generation MS DMTs interferon (IFN)-β-1b, IFN-β-1a IM, and glatiramer acetate with contemporaneously approved biologic tumor necrosis factor (TNF) inhibitors. Results: First-generation DMTs, originally costing $8,000 to $11,000, now cost about $60,000 per year. Costs for these agents have increased annually at rates 5 to 7 times higher than prescription drug inflation. Newer DMTs commonly entered the market with a cost 25%-60% higher than existing DMTs. Significant increases in the cost trajectory of the first-generation DMTs occurred following the Food and Drug Administration approvals of IFN-β-1a SC (2002) and natalizumab (reintroduced 2006) and remained high following introduction of fingolimod (2010). Similar changes did not occur with TNF inhibitor biologics during these time intervals. DMT costs in the United States currently are 2 to 3 times higher than in other comparable countries. Conclusions: MS DMT costs have accelerated at rates well beyond inflation and substantially above rates observed for drugs in a similar biologic class. There is an urgent need for clinicians, payers, and manufacturers in the United States to confront the soaring costs of DMTs.

AB - Objective: To examine the pricing trajectories in the United States of disease-modifying therapies (DMT) for multiple sclerosis (MS) over the last 20 years and assess the influences on rising prices. Methods: We estimated the trend in annual drug costs for 9 DMTs using published drug pricing data from 1993 to 2013. We compared changes in DMT costs to general and prescription drug inflation during the same period. We also compared the cost trajectories for first-generation MS DMTs interferon (IFN)-β-1b, IFN-β-1a IM, and glatiramer acetate with contemporaneously approved biologic tumor necrosis factor (TNF) inhibitors. Results: First-generation DMTs, originally costing $8,000 to $11,000, now cost about $60,000 per year. Costs for these agents have increased annually at rates 5 to 7 times higher than prescription drug inflation. Newer DMTs commonly entered the market with a cost 25%-60% higher than existing DMTs. Significant increases in the cost trajectory of the first-generation DMTs occurred following the Food and Drug Administration approvals of IFN-β-1a SC (2002) and natalizumab (reintroduced 2006) and remained high following introduction of fingolimod (2010). Similar changes did not occur with TNF inhibitor biologics during these time intervals. DMT costs in the United States currently are 2 to 3 times higher than in other comparable countries. Conclusions: MS DMT costs have accelerated at rates well beyond inflation and substantially above rates observed for drugs in a similar biologic class. There is an urgent need for clinicians, payers, and manufacturers in the United States to confront the soaring costs of DMTs.

UR - http://www.scopus.com/inward/record.url?scp=84929871469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929871469&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000001608

DO - 10.1212/WNL.0000000000001608

M3 - Article

VL - 84

SP - 2185

EP - 2192

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 21

ER -